TipRanks
Enovis (CH:C520)
:C520

Enovis (C520) Price & Analysis

0 Followers

C520 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Organic Growth And Share GainsPositive organic growth across both segments, particularly in Reconstruction, indicates continued demand and commercial execution. Growth in hips, knees, shoulders, and extremities, together with reported share-gain opportunities, can support durable revenue expansion over the next several quarters.
Product Innovation And AdoptionNebula conversions and the commercial launch of ARVIS strengthen Enovis’s technology and product portfolio. Adoption by competitive users and positive early feedback can deepen surgeon engagement, support account wins, and create a foundation for sustained share gains.
Improving Cash Flow And MarginsImproving margins and sharply higher free cash flow show progress toward better earnings quality and internal funding capacity. Reaffirmed expectations for over 25% free-cash-flow conversion would strengthen debt reduction and provide more flexibility for innovation and growth investment.
Bears Say
Large Ongoing Net LossesVery large reported losses remain the clearest fundamental weakness and indicate that revenue growth has not yet translated into consistent GAAP earnings power. Until profitability improves materially, Enovis may have less resilience to operational setbacks and less capacity to fund expansion from earnings.
Elevated LeverageLeverage near the level of equity limits financial flexibility relative to a less indebted balance sheet. Although management is targeting leverage below three times, debt reduction depends on sustained cash generation, making capital allocation and execution more consequential over the coming quarters.
Inflation And Pricing PressurePersistent inflation can pressure margins when contractual and competitive conditions prevent full price recovery. The issue is especially relevant in Prevention & Recovery, where management has already identified difficulty passing through costs, potentially limiting the durability of margin expansion.

Enovis News

C520 FAQ

What was Enovis’s price range in the past 12 months?
Currently, no data Available
What is Enovis’s market cap?
Enovis’s market cap is CHF983.78M.
    When is Enovis’s upcoming earnings report date?
    Enovis’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
      How were Enovis’s earnings last quarter?
      Enovis released its earnings results on Aug 06, 2026. The company reported CHF0.739 earnings per share for the quarter, beating the consensus estimate of CHF0.695 by CHF0.044.
        Is Enovis overvalued?
        According to Wall Street analysts Enovis’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Enovis pay dividends?
          Enovis does not currently pay dividends.
          What is Enovis’s EPS estimate?
          Enovis’s EPS estimate is 0.63.
            How many shares outstanding does Enovis have?
            Enovis has 57,669,495 shares outstanding.
              What happened to Enovis’s price movement after its last earnings report?
              Enovis reported an EPS of CHF0.739 in its last earnings report, beating expectations of CHF0.695. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of Enovis?
                Currently, no hedge funds are holding shares in CH:C520
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Enovis

                  Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

                  Enovis (C520) Earnings & Revenues

                  C520 Company Deck

                  C520 Earnings Call

                  Q2 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call was broadly positive. Enovis delivered 5% organic growth, strong U.S. Recon and new-product momentum, improved margins, higher adjusted EPS, a significant improvement in free cash flow, and progress on deleveraging while reaffirming 2026 guidance. The principal challenges were inflation, tariffs, Middle East-related disruption, softer Western European markets, and a seasonally more difficult third quarter, but management expressed confidence in commercial execution and second-half acceleration.View all CH:C520 earnings summaries

                  C520 Stock 12 Month Forecast

                  Average Price Target

                  ―
                  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
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Conmed
                  ―
                  ―
                  Integra Lifesciences
                  ―
                  ―
                  Smith & Nephew Snats
                  ―
                  ―
                  Stryker
                  ―
                  ―
                  Zimmer Biomet Holdings
                  ―
                  ―
                  Popular Stocks